Trial · NCT07902128
A Single-Center Phase 1 Study of ceAF for Knee Osteoarthritis (KOA)
NCT07902128, Phase 1, Recruiting, Anhui HygeianCells BioMedical Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Single-Center Phase 1 Study of ceAF for Knee Osteoarthritis (KOA). Trials, record NCT07902128. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07902128
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Single-Center Phase 1 Study of ceAF for Knee Osteoarthritis (KOA)
- NCT number
- NCT07902128
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 26 participants, estimated
- Lead sponsor
- Anhui HygeianCells BioMedical Co., Ltd.
- Conditions
- Knee Arthritis, Osteoarthritis
- Interventions
- Animal early embryo extract
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety observation | From informed consent signature through 12 weeks after the last injection | Number and percentage of participants with any adverse event, treatment-related adverse event, serious adverse event and adverse event leading to discontinuation, graded by CTCAE v5.0; includes clinically significant changes in vital signs, ECG and laboratory parameters. |
| Primary | Change from baseline in knee joint X-ray findings | Baseline (screening) and 4 and 12 weeks after the last injection | Change in Kellgren-Lawrence grade and medial joint space width on weight-bearing anteroposterior radiograph of the index knee, compared with the screening radiograph. |
| Primary | Change from baseline in Knee injury and Osteoarthritis Outcome Score (KOOS) | Baseline (screening) and 4 and 12 weeks after the last injection | Change in the five KOOS subscales (pain, symptoms, activities of daily living, sport and recreation, knee-related quality of life), each scored 0-100, where 100 indicates no problems. |
| Primary | Change from baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) | Baseline (screening) and 4 and 12 weeks after the last injection | Change in the WOMAC pain, stiffness and physical function subscales (visual analogue scale version), scale 0-96, higher scores mean worse outcome. |
| Primary | Change from baseline in knee pain on a visual analogue scale (VAS) | Baseline (screening) and 4 and 12 weeks after the last injection | Change in participant-rated knee pain on a 0-10 VAS (0 = no pain, 10 = worst imaginable pain), assessed at least 3 days after discontinuation of all analgesic medication. |
| Secondary | Change from baseline in pain-free walking distance | Baseline (screening) and 4 and 12 weeks after the last injection | Change in the maximum distance walked on a flat surface without knee pain, compared with screening. |
| Other | Change from baseline in knee joint MRI findings | Baseline (screening) and 4 and 12 weeks after the last injection | Change in cartilage morphology, cartilage thickness and subchondral bone marrow lesions on 3.0 T MRI of the index knee, assessed with a semi-quantitative scoring system, compared with the screening MRI. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07902128
GET https://conductscience.org/api/trials/v1/NCT07902128/registered